All media enquiries:

AAIC21: Cognito’s gamma frequency neuromodulation reduces brain atrophy in Alzheimer’s trial

July 26, 2021

Cognito Therapeutics Presents New Clinical Data Demonstrating Disease-Modifying Effects of Gamma Frequency Neuro-modulation on Cognitive Function and Brain Atrophy in Alzheimer’s Disease at AAIC 2021

July 26, 2021

Advancing Breakthrough Treatments for a Novel Class of Neurodegenerative Targets in Alzheimer’s Disease

July 22, 2021

Cognito Therapeutics Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2021

July 14, 2021

Cognito Therapeutics Appoints Gerald Chan as Chairman of the Board

July 6, 2021

Cognito Therapeutics Initiates Studies in Down Syndrome Associated Alzheimer’s Disease

June 14, 2021

Moving Beyond Traditional Approaches to Alzheimer’s Disease

June 8, 2021

Cognito Therapeutics Appoints Everett Crosland as Chief Commercial Officer

May 18, 2021

MCIT Ruling Increases Access to Digital Therapeutic Innovation

May 3, 2021